Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 4c

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of ($0.53), $0.04 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $6 million versus the consensus estimate of $4.7 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
• Navan, Inc. (NAVN) Tops Q2 EPS by 1c, Offers Guidance
• Cooper Cos. (COO) Tops Q3 EPS by 3c, Offers Guidance